Skip to main content

Relugolix Dosage

Medically reviewed by Last updated on Feb 11, 2021.

Applies to the following strengths: 120 mg

Usual Adult Dose for Prostate Cancer

Loading Dose: 300 mg orally once on the first day
Maintenance Dose: 120 mg orally once a day

-Treatment is usually continued upon development of nonmetastatic or metastatic castration-resistant prostate cancer in patients treated with GnRH receptor agonists and antagonists.

Use: For the treatment of adult patients with advanced prostate cancer

Renal Dose Adjustments

Data not available.

Liver Dose Adjustments

Data not available.

Dose Adjustments

- Coadministration should be avoided.
-If unavoidable, take this drug and separate dosing 6 hours apart.
-If a short course with P-gp inhibitor is required, treatment with this drug may be interrupted for up to two weeks.
-If treatment is interrupted for more than 7 days, resume with a 360 mg loading dose on the first day and continue with 120 mg once a day.

-Coadministration Should be avoided.
-If unavoidable, increase the dose of this drug to 240 mg once a day.
-May resume at the recommended dose after discontinuation of the combined P-gp and strong CYP450 3A inducer.



Safety and efficacy have not been established in patients younger than 18 years.

Consult WARNINGS section for additional precautions.


Data not available.

Other Comments

Administration advice:
-The tablets should be swallowed whole.
-Do not to crush or chew tablets.
-This drug can be taken with or without food at approximately the same time each day.
-Take a missed dose as soon as possible.
-If a dose is missed and cannot be taken within 12 hours, skip that dose and take the next dose at the usual time.
-If treatment is interrupted for greater than 7 days, restart with a loading dose of 360 mg on the first day and continue with a dose of 120 mg once a day.

Storage Requirements:
-Store at room temperature.
-Do not store above 30C (86F).

-Cardiovascular: ECG
-Endocrine: Prostate specific antigen levels
-Metabolic: Serum electrolytes

Patient advice:
-Advise the patient to read the FDA-approved patient labeling.
-Inform patients that this drug can be harmful to a developing fetus and can cause loss of pregnancy.
-Advise males with female partners of reproductive potential to use effective contraception during therapy and for at least 2 weeks after the last dose.
-Advise patients that this drug may prolong the QT interval and to report any signs of symptoms of QT prolongation.
-Inform patients that this drug may cause hot flashes, flushing of the skin, increased weight, decreased sex drive, and difficulties with erectile function.
-Inform patients that this drug may cause infertility.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.